Skip to main content

Drug Interactions between nirsevimab and Synagis

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

palivizumab nirsevimab (cvx 306)

Applies to: Synagis (palivizumab) and nirsevimab

GENERALLY AVOID: Data are not available regarding the administration of palivizumab in infants who have already received prophylactic therapy with nirsevimab. Palivizumab is a monoclonal antibody targeting the fusion (F) protein of the respiratory syncytial virus (RSV) and requires monthly administration for maintenance of effect. Nirsevimab is a long-acting monoclonal antibody that targets the prefusion form of RSV F protein. According to the manufacturer of nirsevimab, there are also no data regarding the substitution of nirsevimab for palivizumab once prophylactic therapy is commenced with palivizumab.

MANAGEMENT: The use of palivizumab in infants who have already received nirsevimab in the same RSV season is not recommended. According to the manufacturer, nirsevimab may be administered prior to or during the second RSV season in children up to 24 months of age who continue to be vulnerable to severe RSV disease, and who received palivizumab therapy in their first RSV season.

References (2)
  1. (2023) "Product Information. Beyfortus (cvx 307) (nirsevimab (cvx 307))." sanofi pasteur
  2. Esposito S, Abu Raya, B, Baraldi E, Flanagan, K, Martinon Torres, F, Tsolia, M, Zielen, S (2022) "RSV prevention in all infants: which is the most preferable strategy?" Front. Immunol., 13, p. 1-13

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

Therapeutic duplication is the use of more than one medicine from the same drug category or therapeutic class to treat the same condition. This can be intentional in cases where drugs with similar actions are used together for demonstrated therapeutic benefit. It can also be unintentional in cases where a patient has been treated by more than one doctor, or had prescriptions filled at more than one pharmacy, and can have potentially adverse consequences.

Duplication

Rsv immune globulins

Therapeutic duplication

The recommended maximum number of medicines in the 'RSV immune globulins' category to be taken concurrently is usually one. Your list includes two medicines belonging to the 'RSV immune globulins' category:

  • nirsevimab
  • Synagis (palivizumab)

Note: In certain circumstances, the benefits of taking this combination of drugs may outweigh any risks. Always consult your healthcare provider before making changes to your medications or dosage.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer